FDA-approved·GLP-1 agonist
Semaglutide
aka Ozempic, Wegovy, Rybelsus
Education only. Many compounds discussed are research chemicals not approved for human use in the US. This is not medical advice — consult a licensed physician.
What it is
FDA-approved GLP-1 receptor agonist. Ozempic for type 2 diabetes, Wegovy for chronic weight management, Rybelsus for oral T2D.
How it works
Activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion.
What the research says
STEP trials showed ~15% weight loss at 68 weeks at 2.4mg/week.
Sources: STEP-1 NEJM · FDA Wegovy label
Common dosing ranges
- Range
- Start 0.25 mg/week, titrate to 2.4 mg/week
- Frequency
- Once weekly (subQ); daily for oral form
- Duration
- Long-term per FDA label
Sources: FDA label
Administration
SubQ · Oral
Half-life
~7 days
Side effects
Common
- Nausea
- Diarrhea
- Vomiting
- Constipation
Serious / theoretical
- Pancreatitis
- Gallbladder disease
- Thyroid C-cell tumor warning
Sources: FDA label